Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Settles On Paxil Data Disclosure, Will Post Past Study Results By 2006

Executive Summary

GlaxoSmithKline will post summaries of studies conducted since the merger of Glaxo Wellcome and SmithKline Beecham by the end of 2005 under a settlement with New York Attorney General Eliot Spitzer

You may also be interested in...



Negative Antidepressant Trial Results See Low Publication Rate, Study Finds

The vast majority of antidepressant clinical trials viewed by FDA as having negative or questionable results are either not published in medical journals or published in a way that conveys a positive outcome, according to results of a study published in the January 17 issue of the New England Journal of Medicine

Negative Antidepressant Trial Results See Low Publication Rate, Study Finds

The vast majority of antidepressant clinical trials viewed by FDA as having negative or questionable results are either not published in medical journals or published in a way that conveys a positive outcome, according to results of a study published in the January 17 issue of the New England Journal of Medicine

ClinicalTrials.Gov Compliance Varies By FDA Review Division, Report Finds

Industry participation in HHS' ClinicalTrials.gov database fluctuated widely by FDA review division, according to an agency report on the progress of implementing the federally-mandated database

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel